Posts Tagged ‘ADLS’

Daily Pharma Watch (Update in Process)

August 10th, 2010

Alright pharma investors time for the daily pharma watch, but before I start I would also like to let you that I will be doing what I call the “Deal of the Day.” This is where I partner with an affiliate to bring you a deal that you can’t get elsewhere, I have tons of great coupons at my fingertips, so if you are looking for some type of product let me know and I’ll see what I can dig up. Today I have partnered with Trade King to bring my fellow investors a good deal. Simply follow the link below and you will get a FREE $50 when you open an account with TradeKING, that’s right $50!

Get $50 when you open a TradeKing account today.

Advanced Life Sciences (ADLS):

Advanced Life Sciences announced some positive news this morning. The company said that they have finally reached an agreement with the FDA to run their follow up Phase III clinical trial of Restanza under a Special Protocol Assessment designation for patients with community acquired bacterial pneumonia. The study is designed to show that Restanza has superior efficacy over other medicines who have become resistant to macrolide drugs. » Read more: Daily Pharma Watch (Update in Process)

No comments »

Posted in Uncategorized

Tags:

Daily Pharma Watch

July 28th, 2010

Generex (GNBT):

Generex said this morning that they had now achieved 75% of the required number of per-protocol completers in its Phase III trial of Oral-lyn. The company noted that early results may suggest that the use of Oral-lyn will support a non-inferiority claim relative to standard of care injectable insulin. The company reiterated that patients taking Oral-lyn on average showed no weight gain and an actual decrease in Body Mass Index (BMI). » Read more: Daily Pharma Watch

No comments »

Posted in Uncategorized

Tags:

Daily Pharma Watch

July 26th, 2010

Onyx Pharmaceuticals (ONXX):

This morning Onyx made some major announcements. The company said that one of their lead drugs in development, carfilzomib, showed strong results in a Phase IIb study in relapsed and refractory multiple myeloma patients. The company noted that 24% of patients achieved an overall response rate and had a median duration of response of 7.4 months with very few side effects. » Read more: Daily Pharma Watch

4 comments »

Posted in Uncategorized

Tags:

Daily Pharma Watch

July 23rd, 2010

Alright Pharma Investors time for the daily pharma watch. But first, I would like to point out some other interesting news because it is pretty relevant for small cap investors in the health care arena. My website usually follows smaller cap pharmaceutical companies, but I also keep a very close eye on the larger cap pharma companies and one that I have been following particularly close is Eli Lilly. » Read more: Daily Pharma Watch

2 comments »

Posted in Uncategorized

Tags:

Daily Pharma Watch

May 26th, 2010

Vertex Pharmaceuticals (VRTX):

Vertex announced some positive results this morning from the Phase III trial of their hepatitis C drug telaprevir. The company said that 75% of people chronically infected with genotype 1 heaptitis C achieved a sustained viral response after receiving a 12 week regimen. Sustained Virological response is defined as the absence of HCV RNA from serum by a sensitive PCR assay 24 weeks following discontinuation of therapy. » Read more: Daily Pharma Watch

No comments »

Posted in Uncategorized

Tags: